Phosphorylated MAPK14 Promotes the Proliferation and Migration of Bladder Cancer Cells by Maintaining RUNX2 Protein Abundance

This article was published in the following Dove Press journal:
Cancer Management and Research

Junlong Liu ¹
Xiuyue Yu¹
Bitian Liu²
Hongyuan Yu¹
Zhenhua Li ¹

¹Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, People's Republic of China; ²Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, People's Republic of China

Background: Mitogen-activated protein kinase 14 (*MAPK14*) acts as an integration point for multiple biochemical signal pathways. High expressions of *MAPK14* have been found in a variety of tumors. Runt-related transcription factor 2 (*RUNX2*) is related to many tumors, especially in tumor invasion and metastasis. However, the mechanism of these two genes in bladder cancer remains unclear.

Methods: TCGA database and Western blot were used to analyze the mRNA and protein levels of the target gene in bladder cancer tissues and adjacent tissues. The proliferation ability of bladder cancer cells was tested by colony forming and EdU assay. The migration ability of cells was detected by transwell assay. Immunoprecipitation was utilized to detect protein–protein interaction. Cycloheximide chase assay was used to measure the half-life of *RUNX2* protein.

Results: Phosphorylated mitogen-activated protein kinase 14 (*P-MAPK14*, Thr180/Tyr182) was highly expressed in bladder cancer tissues and bladder cancer cell lines. Accordingly, *P-MAPK14* could be combined with *RUNX2* and maintain its protein stability and promote the proliferation and migration of bladder cancer cells. In addition, the functional degradation caused by the downregulation of *MAPK14* and *P-MAPK14* could be partially compensated by the overexpression of *RUNX2*.

Conclusion: These results suggest that *P-MAPK14* might play an important role in the development of bladder cancer and in the regulation of *RUNX2* protein expression. *P-MAPK14* might become a potential target for the treatment of bladder cancer.

Keywords: *MAPK14*, *RUNX2*, *P-MAPK14*, bladder cancer, ubiquitination

Introduction

Bladder cancer, the ninth most common cancer worldwide, is a highly heterogeneous disease and an important cause of cancer metastasis-related death.¹ In the United States, it has been estimated that there would be about 80,470 new bladder cancer cases and 17,670 deaths in 2019.² The incidence of bladder cancer is higher in males and 70% of patients with bladder cancer are initially diagnosed as non-muscular invasive diseases. There are several risk factors related to bladder cancer, such as smoking, aging and exposure to the products of chemical industries.^{1,3} In recent years, despite the progress in clinical diagnosis and treatment of bladder cancer, it remains to be a perplexing problem in clinical management due to its high metastasis rate.⁴ Therefore, a comprehensive understanding of the pathogenetic mechanism of bladder cancer would improve the prognosis of patients.

Correspondence: Zhenhua Li
Department of Urology, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Liaoning 110001, People's Republic of China
Email lizhenhua_cmu@163.com

P38 mitogen-activated protein kinase (*MAPK*) contains four isoforms (α , β , γ , δ), which are encoded by four different genes, sharing a sequence with high homology.^{5,6} *MAPK14* is a member of the *P38 MAPK* family, also called *P38 α* .⁷ It has been reported that *MAPK14* plays an important role in coordinating DNA damage response and limiting chromosomal instability during breast cancer progression. Moreover, reduced *MAPK14* level leads to DNA damage and increased chromosomal instability in breast cancer cells, ultimately resulting in cancer cell death and tumor regression.⁸ However, *MAPK14* plays a dual role in colon tumors. *MAPK14* protects intestinal epithelial cells from colon cancer-related colitis by regulating the function of the intestinal epithelial barrier, but it also contributes to the maintenance of colon tumors.⁹ In bladder cancer, although some studies have pointed out that *MAPK14* signaling pathway is involved in promoting or inhibiting the proliferation and migration of tumor cells, most of the studies are not directed at *MAPK14*.^{10–12} Therefore, the mechanism of *MAPK14* gene in bladder cancer remains to be clarified, and further study is necessary.

As a key factor of osteoblast differentiation, transcription factor Runt-related transcription factor 2 (*RUNX2*) plays a crucial role in osteoblast differentiation.^{13,14} *RUNX2* is a member of the mammalian *RUNX* family of transcription factors, and it has been shown to be involved in tumor development.¹⁵ Phosphorylated *RUNX2* is tightly related to the metastasis of prostate cancer.¹⁶ Overexpression of *RUNX2* could increase the cancer cell proliferation in mantle cell lymphoma.¹⁷ In addition, it has been reported that *RUNX2* and *p53* may be functionally related to bladder cancer, and may be associated with the development and invasion of bladder tumors.¹⁸ However, the expression pattern and the role of *RUNX2* in bladder cancer require to be elucidated.

In this study, the transcriptional level of *MAPK14* in bladder urothelial carcinoma from the TCGA database was analyzed, and it was shown that *MAPK14* was poorly expressed in bladder cancer tissues, both in the overall analysis and in the analysis of 19 paired samples. Then, protein levels of *MAPK14* and phosphorylated *MAPK14* (*P-MAPK14*) in bladder cancer tissues and bladder cancer cell lines were investigated. It was found that *P-MAPK14* was highly expressed in both bladder cancer tissues and bladder cancer cell lines. After *MAPK14* protein was knocked down by small interfering RNA (siRNA), the level of *P-MAPK14* protein declined, and the clonal

formation, proliferation and migration ability of bladder cancer cells decreased. Downregulation of *P-MAPK14* protein did not reduce the *RUNX2* mRNA level but resulted in the decrease of *RUNX2* protein abundance. Co-immunoprecipitation assay indicated that *P-MAPK14* might interact with *RUNX2*. Further studies revealed that *P-MAPK14* might preserve the stability of *RUNX2* protein by reducing its ubiquitination degradation pathway. This study suggested that *P-MAPK14* might promote bladder cancer cell proliferation and migration by maintaining the stability of *RUNX2* protein.

Materials and Methods

The Cancer Genome Atlas (TCGA) Data

TCGA is a program for retrieving and processing data from the open access GDC data portal. From pre-treated bladder urothelial carcinoma, 414 cancer samples were selected, including 19 pairs of matched bladder urothelial carcinoma tissues and adjacent normal tissues, and the target gene *MAPK14* was analyzed.

Tissue Samples

Thirty-six cases of bladder cancer with adjacent normal tissues were collected. The patients did not receive pre-operative chemoradiotherapy, and the adjacent normal tissues obtained were at least 5 cm away from the cancer tissues. The tissue was stored in the refrigerator at -80°C before use. Informed consent was signed by all patients and the study was approved by the Ethics Committee of the First Hospital of China Medical University.

Cell Culture and Treatment

Human bladder cancer cells 5637, UMUC3, T24, J82 and immortalized human urothelial cells SV-HUC were cultured in RPMI-1640 (HyClone, USA) medium. The medium was supplemented with 10% fetal bovine serum (HyClone, USA). All cell lines were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and were cultured under humidified air containing 5% CO_2 at 37°C . When the confluence of cells reached at 80%, the cells were digested with trypsin for subculture.

VX-702, cycloheximide (CHX) and MG-132 were purchased from MCE (MedChemExpress, USA). Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (St Louis, MO, USA). The cells were treated with VX-702 (20 nmol/L) for 24 hours or 48 hours before the

protein was extracted for analysis. To explore the degradation pathway of *RUNX2*, MG-132 (20 $\mu\text{mol/L}$) was added to stabilize the cell lines with *shMAPK14* for 4 hours, and then the proteins were collected for Western blot analysis. The method for determining the half-life of *RUNX2* protein by cyclohexylamine was described earlier.¹⁹ After 48 hours of transfection, cells were treated with CHX (100 $\mu\text{g/mL}$) for the indicated time.

siRNAs and Plasmids Transfection

The siRNAs of *MAPK14* were synthesized by JTSBIO Co (China). The *MAPK14* siRNA and negative control siRNA (*siNC*) sequences were used as follows (5'-3'): *siMAPK14*#1 sense, CCAGACCAUUUCAGUCCAUTT and anti-sense, AUGGACUGAAAUGGUCUGGTT; *siMAPK14*#2 sense, CCUUGCACAUGCCUACUUUTT and anti-sense, AAAGUAGGCAUGUGCAAGGTT; *siNC* sense, UUCUCCGAA CGUGUCACGUTT and anti-sense, ACGUGACACGUUC GGAGAATT. The plasmids for empty vector, *shMAPK14* and *OE-RUNX2* were purchased from GeneChem (Shanghai, China). Lipofectamine[®]3000 Transfection Kit (Invitrogen) was used for transfection and the specific dose was determined according to the manufacturer's instructions. RNA or protein was extracted when the transfection time reached 24 or 48 hours. In addition, cell lines stably downregulating *MAPK14* (*shMAPK14*) were screened with puromycin (2 $\mu\text{g/mL}$) for 4 weeks.

Western Blot

Total protein of tissues and cells lines was extracted with RIPA lysates (containing protease and phosphatase inhibitors). Protein concentration was detected using a BCA Protein Assay Kit (Beyotime, China). The equal amount of protein was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Then, proteins were transferred onto polyvinylidene fluoride membranes (BIO-RAD, USA). After blocked by 5% skim milk for 1 hour, the proteins were then tested with the following antibodies: anti-*MAPK14* (1:1000, 9218, CST), anti-*P-MAPK14* (1:1000, 4511, CST), anti-*RUNX2* (1:1000, 12,556, CST), anti-*Tubulin* (1:1000, 2128S, CST), anti-*GAPDH* (1:1000, 5174, CST) at 4°C overnight. The membrane was subsequently incubated with the secondary anti-rabbit antibody at 37°C for 1 hour. Finally, the luminescence system (Bio-Rad, CA, USA) and ECL luminescence reagent were used for detection (Absin Biotechnology, Shanghai, China). ImageJ software (USA) was used for quantitative analysis. Protein abundance was normalized with *tubulin* or *GAPDH*.

RNA Extraction and qPCR

Total RNA of bladder cancer cells was extracted with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed using PrimeScript[™] RT reagent Kit (Takara, Japan) following the manufacturer's instructions. QPCR analyses were performed using TB Green[®] Premix Ex Taq[™] II (Takara, Japan). *GAPDH* was used as the internal reference. The $2^{-\Delta\Delta\text{CT}}$ method was used for detection of the relative expression level. Primer sequences designed for target genes were as follows: *MAPK14* sense, CCCGA GCGTTACCAGAACC and anti-sense, TCGCATGAA TGATGGACTGAAAT; *RUNX2* sense, GCGCATTCCT CATCCCAGTA and anti-sense, GGCTCAGGTAGGAG GGGTAA; *GAPDH* sense, ACAACTTTGGTATCGTG GAAGG and anti-sense, GCCATCACGCCACAGTTTC.

Co-Immunoprecipitation

The cells were washed with precooled 1×PBS when the confluence of cells reached at 90%, and 0.5 mL of cold 1×RIPA lysates was added into the culture dish. After centrifugation at 4°C, 14,000 g for 30 min, the supernatant was transferred to the new tube. The primary antibody was added into the cell lysate, and then the lysate containing the antibody was rotated overnight at 4°C. The magnetic beads were then added to the pyrolysis solution and the mixture was rotated at 4°C for 4 hours. The magnetic beads were extracted with a magnetic rack, and the denaturation was expected to continue with the Western blot procedure. Negative control IgG was acquired from Cell Signaling Technology (1:20, 5873S, CST).

Cell Colony Forming

The transfected cells were collected and counted, and then redeposited into the six-well plates to reach 500 cells per well. After 10 days of culture at 37°C with 5%CO₂, the cells in the six-well plate were stained with crystal violet for 10 minutes. The cells were photographed and counted to evaluate the viability and proliferation of individual cells.

EdU Assay

The cells were planted in 24-well plates. After 48 h transfection, EdU (1:1000) reagent was added (BeyoClick[™], EDU-488, China). Culture was continued for another 2 hours, and experiments were conducted according to the manufacturer's instructions. Finally, the number of proliferating cells was

counted by taking photos under a fluorescence microscope (Olympus Corporation, Japan).

Cell Migration Assay

Cell migration ability was analyzed using transwell chamber (Corning, USA). Cells were collected and counted after transfection for 48 hours. The transwell chamber was placed in advance in 600 μ L of serum medium, and 10,000 cells were seeded with 200 μ L of serum-free medium into the upper chamber. After 12 hours of culture in the incubator, the chamber was taken out and stained with crystal violet for 10 minutes. Then, cells in the upper chamber were gently wiped off with cotton swabs. Images were taken under a microscope and analyzed with ImageJ.

Statistical Analysis

The data from at least three independent experiments were expressed as mean $\pm$ standard deviation (SD). Differences between groups were analyzed by Student's *t*-test. Statistical analysis was conducted with GraphPad Prism version 7.0 (La Jolla, CA, USA). $P < 0.05$ was considered statistically significant (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ^{ns} $P > 0.05$).

Results

Phosphorylated MAPK14 is Highly Expressed in Bladder Cancer Tissues and Bladder Cancer Cell Lines

In the TCGA database, the transcriptional expression level of *MAPK14* was analyzed, and it was found that mRNA expression of *MAPK14* was low in bladder cancer tissues in either the overall analysis or the paired analysis (Figure 1A and B). Considering that *P-MAPK14* is the main activation form of *MAPK14*, the expression levels of *MAPK14* and *P-MAPK14* in 36 pairs of bladder cancer specimens and matched adjacent non-cancerous bladder tissues were analyzed by immunoblotting. The protein level of *MAPK14* in bladder cancer samples was not statistically significant with that in adjacent non-cancerous tissues, while *P-MAPK14* in bladder cancer samples was significantly higher than that in adjacent tissues (Figure 1C–F). Moreover, compared with SV-HUC (immortalized human urothelial cells), high protein expression of *P-MAPK14* was also observed in 5637, T24, and UMUC3 cell lines (Figure 1G). These findings suggest that *P-MAPK14* was overexpressed in both human bladder cancer cell lines and bladder cancer tissues.

Downregulation of MAPK14/P-MAPK14 Protein Can Inhibit Proliferation and Migration of Bladder Cancer Cells

The role of *MAPK14* in promoting cell proliferation and migration in many tumors has been ascertained by many studies. To reveal the function of *P-MAPK14* in bladder cancer cells, the biological function of *P-MAPK14* in bladder cancer cells was studied. As showed by Western blot, the protein levels of *MAPK14* and *P-MAPK14* were significantly reduced by *MAPK14* siRNA (Figure 2A). Colony formation assay showed that the T24 and UMUC3 cells colony formation ability were impeded by depletion of *MAPK14* (Figure 2B). Similarly, EdU assay showed that the proliferation ability of bladder cancer cells T24 and UMUC3 were decreased significantly after 48 hours of cell transfection with *MAPK14* siRNA (Figure 2C). To investigate the effect of *P-MAPK14* in bladder cancer cell migration, cell lines T24 and UMUC3 with high metastatic ability were used. Consistently, migration assay showed that cells migration ability was reduced by the silencing of *MAPK14* and *P-MAPK14* (Figure 2D). These results suggest that *MAPK14* and *P-MAPK14* might be involved in cell clonal formation, proliferation, and migration.

P-MAPK14 Regulates the RUNX2 Protein Expression in Bladder Cancer Cells

It has been shown that lack of *MAPK14* can lead to the decrease in *RUNX2* protein level.²⁰ To study whether *P-MAPK14* can regulate the *RUNX2* protein in bladder cancer cells, endogenous *MAPK14* was knocked down with two independent siRNAs in T24 and UMUC3 cells. The *MAPK14* mRNA level was significantly decreased, but the *RUNX2* mRNA level was increased in T24 cells. Similarly, *RUNX2* was an upregulated trend in UMUC3 cell lines, whereas it was not statistically significant (Figure 3A). Western blot was used to explore whether the translation level of *RUNX2* can be changed by the downregulation of *MAPK14* and *P-MAPK14* proteins. In surprise, in the absence of *MAPK14* and *P-MAPK14* proteins, *RUNX2* protein level declined and was inconsistent with the transcriptional level (Figure 3B). Since the siRNA of *MAPK14* could simultaneously reduce the protein levels of *MAPK14* and *P-MAPK14*, in order to explore whether the decrease of *RUNX2* protein was caused by the decrease of *P-MAPK14*, the inhibitor VX-702 of *P-MAPK14* was utilized in this study, which can reduce the phosphorylation level of *MAPK14* without the degradation of *MAPK14*.

Figure 1 *P-MAPK14* protein was upregulated in bladder cancer samples and bladder cancer cells lines. (A and B) In the TCGA database, the transcriptional expression level of *MAPK14* in bladder cancer tissues was low in either the overall analysis or the paired analysis; (C and D) *MAPK14* protein levels in 36 pairs of bladder cancer tissues (C) and adjacent non-cancerous bladder tissues (N); (E and F) *P-MAPK14* protein levels in 36 pairs of bladder cancer tissues (C) and adjacent non-cancerous bladder tissues (N); (G) *P-MAPK14* and *MAPK14* protein levels were detected in bladder cancer cells lines and SV-HUC cells by Western blot assay. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ns $P > 0.05$).

protein. Western blot result showed that *RUNX2* protein abundance was decreased significantly with the decrease of *P-MAPK14* protein level (Figure 3C). In order to investigate whether *RUNX2* can affect the stability of *MAPK14* and *P-MAPK14* protein, bladder cancer cell lines over-expressing *RUNX2* protein was constructed. Western blot showed that *RUNX2* overexpression had no effect on *MAPK14* and *P-MAPK14* protein levels compared with empty vector group (Figure 3D). To investigate the regulatory relationship between *P-MAPK14* and *RUNX2*, immunoprecipitation assay was performed in two bladder cancer cell lines T24 and UMUC3, Western blot result showed that *P-MAPK14* and *RUNX2* might be bind to

each other in the two cell lines (Figure 3E). In summary, the results mainly show that *P-MAPK14* regulates *RUNX2* protein levels.

P-MAPK14 Maintains the Stability of the RUNX2 Protein

To determine the effect of *P-MAPK14* on the stability of *RUNX2* protein, T24 and UMUC3 cells stably expressing empty vector or *shMAPK14* were treated with DMSO or MG-132 (20 $\mu\text{mol/L}$), a proteasome inhibitor, for 4 hours. Western blot analysis showed that *RUNX2* protein level was decreased due to the absence of *MAPK14*. When cells treated with MG-132, *RUNX2* protein was no significant change

Figure 2 Downregulation of *MAPK14* results in decrease expression of *P-MAPK14* and inhibit bladder cancer cell colony formation, proliferation and migration (**A**) After transfected with *MAPK14* siRNAs in T24 and UMUC3, protein levels of *MAPK14* and *P-MAPK14* were detected by Western blot; (**B**) Downregulation of *MAPK14* suppressed bladder cancer cells colony formation ability; (**C**) EdU assay was used to examine the proliferation ability of T24 and UMUC3 cells (magnification $\times 200$); (**D**) Transwell assay was used to examine the migration ability of T24 and UMUC3 cells (magnification $\times 20$). (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

(Figure 4A). Next, the half-life of the *RUNX2* protein was analyzed by the cycloheximide chase assay. To further determine the effect of *P-MAPK14* on *RUNX2* protein degradation, T24 and UMUC3 cells were transfected with empty vector and *shMAPK14* plasmid, respectively. After transfection for 48 hours, cells were treated with CHX (100 $\mu\text{g/mL}$)

for the indicated time, then harvested the cell protein for immunoblotting. The half-life of the *RUNX2* protein was reduced after *MAPK14/P-MAPK14* depletion (Figure 4B). These results suggest that *MAPK14/P-MAPK14* might regulate the stability of the *RUNX2* protein, probably by inhibiting its ubiquitination degradation pathway.

Figure 3 *P-MAPK14* regulates the *RUNX2* protein expression in bladder cancer cells (**A**) After transfected with *MAPK14* siRNAs in T24 and UMUC3, *MAPK14* and *RUNX2* mRNA levels were determined by RT-PCR; (**B**) *RUNX2* protein levels in T24 and UMUC3 cells were measured by Western blot; (**C**) After T24 and UMUC3 cells were treated with VX-702, protein levels of *MAPK14*, *P-MAPK14* and *RUNX2* were detected by Western blot; (**D**) *MAPK14* and *P-MAPK14* protein expression was detected by Western blot after overexpression of *RUNX2* in T24 and UMUC3 cells; (**E**) The interaction between *P-MAPK14* and *RUNX2* was detected by Co-Immunoprecipitation assay in T24 and UMUC3 cells. (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, $^{ns}P > 0.05$).

Overexpression of RUNX2 Partially Reverses the Reduction in Cell Proliferation and Migration Caused by Reduced MAPK14/P-MAPK14 Expression

The *MAPK14* protein level and *RUNX2* protein level were significantly reduced by *siMAPK14#2*. When *RUNX2* was overexpressed, the *RUNX2* protein level induced by *MAPK14* siRNA was partially restored (Figure 5A).

EdU analysis showed that the proliferation ability of T24 and UMUC3 cells was inhibited when deficiency of *MAPK14* protein, while the function of cell proliferation was partially restored after overexpression of *RUNX2* (Figure 5B). Cell migration test showed that *MAPK14* downregulation diminished the migration of bladder cancer cells, while the reintroduction of *RUNX2* partially restored the activity of *MAPK14* downregulation cells (Figure 5C). These data suggest that *P-MAPK14* might

Figure 4 *P-MAPK14* maintains the stability of the *RUNX2* protein (**A**) Cells stably knockdown of *MAPK14* (sh*MAPK14*) and control group (Vector) were treated with DMSO or MG-132, followed by Western blot assay; (**B**) Cells stably knockdown of *MAPK14* (sh*MAPK14*) and control group (Vector) were treated with 100 μ g/mL cycloheximide for the indicate times. Total cellular lysates were subjected to Western blot assay. (* $P < 0.05$, ** $P < 0.01$).

promote the progression of bladder cancer partially by stabilizing *RUNX2* protein.

Discussion

It has been estimated that *P38 MAPK* can phosphorylate a variety of proteins and may have about 200 to 300 substrates, including many transcription factors. Some targets are downstream kinases that could be activated by phosphorylation. *MAPK14*, one of the four *P38 MAPK*, plays an important role in the cellular cascade caused by extracellular stimuli, such as pro-inflammatory cytokines or physiological stress.^{21–23} As a crucial member of the *P38 MAPK* family, *MAPK14* is highly expressed in a variety of cells and the main form of activation is phosphorylated *MAPK14* (*P-MAPK14*, Thr180/Tyr182).

Our previous in vivo and in vitro studies have shown that knockdown of *MAPK14* can inhibit the proliferation and migration of renal cell clear cell carcinoma.²⁴

Although the transcription level of *MAPK14* analyzed in the TCGA database was low in bladder urothelial carcinoma. This result was likely due to the limited number of normal tissue samples. Our results identified that *P-MAPK14* plays an important role in the proliferation and migration of bladder cancer cells. In the present study, *P-MAPK14* protein expression was detected in bladder cancer tissues and adjacent normal tissues, four bladder cancer cell lines, and one normal urinary epithelial cell line by Western blot assay. The results showed that *P-MAPK14* was highly expressed in both bladder cancer tissues and bladder cancer cell lines. It has been reported

Figure 5 Overexpression of *RUNX2* could partially restore the reduction in proliferation and migration caused by decreased *MAPK14*/*P-MAPK14* levels (**A**) Cells overexpression of *RUNX2* protein and control group (Vector) were transfected with *MAPK14* siRNA or NC, the *MAPK14* and *RUNX2* proteins were detected by Western blot; (**B**) Proliferation ability of T24 and UMUC3 cells was determined by EdU assay (magnification $\times 200$); (**C**) Transwell assay was used to examine the migration ability of T24 and UMUC3 cells (magnification $\times 20$). (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$).

that benzethonium chloride can inhibit the proliferation and promote apoptosis of lung cancer cells by activating *P38 MAPK*.²⁵ In addition, the role of *P-MAPK14* in bladder cancer cells in T24 and UMUC3 was explored in this study. It was found that after the abundance of *P-MAPK14* protein was reduced by *MAPK14* siRNA, the clone formation ability and proliferation and migration ability of cells were significantly decreased. Considering that its main functional form is *P-MAPK14*, and the protein was highly expressed in both bladder cancer tissues and bladder cancer cell lines. It could be hypothesized that *P-MAPK14* might promote the development of bladder cancer.

RUNX2 is the most critical transcription factor when bone marrow mesenchymal stem cells (BMSCS)

differentiate and mature into osteoblasts in the process of bone development.²⁶ Previous studies have shown that *RUNX2* is a major regulator of tumorigenesis and is associated with tumor invasion.^{27,28} In urothelial carcinoma of the bladder, it has been reported that *microRNA-154* and *MicroRNA-217* can directly bind to *RUNX2* mRNA, then inhibit the expression of *RUNX2* protein, resulting in the suppression of bladder cancer progression.^{15,29} In recent years, many studies have reported a correlation between *MAPKs* and *RUNX2* in tumors.^{30,31} Further study has shown that *P38 MAPK* can phosphorylate and activate *RUNX2*.³² In this study, surprisingly, it was found that the transcription level of *RUNX2* was increased by the down-regulation of *MAPK14* and *P-MAPK14* proteins. However,

RUNX2 protein level was not consistent with the transcriptional level. It could be inferred that the increased transcriptional level of *RUNX2* might be provoked by the internal homeostasis due to the decreased *RUNX2* protein level. Since the *RUNX2* protein level decreased after *MAPK14* was downregulated, the inhibitor of *P-MAPK14* was used to further investigate the reasons for the downregulation of *RUNX2* protein. It was noted that *RUNX2* protein level was significantly reduced, indicating that *P-MAPK14* was likely involved in regulating *RUNX2* protein stability. At the same time, it was also found that *P-MAPK14* and *RUNX2* could be bind to each other, which is consistent with the results of bone formation and bone microenvironment studies in mice.³³

RUNX2 protein degradation pathway has been reported and most studies indicate that it is degraded by ubiquitination pathway.^{34,35} In order to detect whether the protein degradation of *RUNX2* was mediated by proteasome, proteasome inhibitors MG-132 was used in this study.³⁶ It was found that MG-132 could effectively increase the expression of *RUNX2* protein, in addition, the protein level of *RUNX2* in the absence of *MAPK14* protein could be recovered to some extent. It has been reported that *MAPK14* could also be degraded by ubiquitination,³⁷ but this phenomenon was not found in our study. After bladder cancer cells were incubated with MG-132, there was no significant difference in protein level of *MAPK14* as compared with the control group. Moreover, cycloheximide tracing experiment showed that the degradation rate of *RUNX2* protein was significantly accelerated in the absence of *MAPK14* protein. In summary, *P-MAPK14* might activate and maintain the stability of the *RUNX2* protein by binding and phosphorylating *RUNX2*. Finally, it was found that the ability of bladder cancer cells proliferation and migration was partially restored by protein rescue experiment.

In conclusion, *P-MAPK14* is highly expressed in bladder cancer tissues, and *P-MAPK14* can promote cell proliferation and migration. Our results also show that *RUNX2* is a substrate of *P-MAPK14*, and *P-MAPK14* can prevent *RUNX2* degradation by binding to it. However, our data do not confirm that downregulation of *MAPK14* and *P-MAPK14* lead to the increase of *RUNX2* transcription and the mechanism of *P-MAPK14* regulating *RUNX2* ubiquitination pathway degradation need further study. Considering that inhibitors of *P-MAPK14* have been identified, these findings might provide a theoretical basis for the treatment of bladder cancer.

Data Sharing Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics Approval and Consent to Participate

The Ethics Committee of the First Hospital of China Medical University (Shenyang, China) approved the use of human tissue samples for experiments. All participants provided written informed consent for the entire study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by Shenyang Plan Project of Science and Technology (Grant No. F19-112-4-098), China Medical University's 2017 discipline promotion program (Grant No. 3110117040), and 2017 National Key R&D Program Key Projects of Precision Medical Research (2017YFC0908000).

Disclosure

The authors declare that they have no conflict of interests.

References

1. Albarakati N, Khayyat D, Dallol A, Al-Maghrabi J, Nedjadi T. The prognostic impact of GSTM1/GSTP1 genetic variants in bladder cancer. *BMC Cancer*. 2019;19:991. doi:10.1186/s12885-019-6244-6.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7–34. doi:10.3322/caac.21551
3. National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management of bladder cancer: © NICE (2015) bladder cancer: diagnosis and management of bladder cancer. *BJU Int*. 2017;120(6):755–765. doi:10.1111/bju.14045
4. Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (tat1 and carcinoma in situ) - 2019 update. *Eur Urol*. 2019;76(5):639–657.
5. Mai L, Zhu X, Huang F, He H, Fan W. p38 mitogen-activated protein kinase and pain. *Life Sci*. 2020;256:117885. doi:10.1016/j.lfs.2020.117885
6. Han J, Wu J, Silke J. An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling. *F1000Res*. 2020;9.

7. Zheng T, Zhang B, Chen C, et al. Protein kinase p38 α signaling in dendritic cells regulates colon inflammation and tumorigenesis. *Proc Natl Acad Sci U S A*. 2018;115(52):E12313–12313 E12322. doi:10.1073/pnas.1814705115
8. Cánovas B, Igea A, Sartori AA, et al. Targeting p38 α increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells. *Cancer Cell*. 2018;33(6):1094–1110. e8. doi:10.1016/j.ccell.2018.04.010
9. Gupta J, Del Barco Barrantes I, Igea A, et al. Dual function of p38 α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. *Cancer Cell*. 2014;25(4):484–500. doi:10.1016/j.ccr.2014.02.019
10. Hendrickx N, Dewaele M, Buytaert E, et al. Targeted inhibition of p38 α MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy. *Biochem Biophys Res Commun*. 2005;337(3):928–935. doi:10.1016/j.bbrc.2005.09.135
11. Wu YJ, Su TR, Dai GF, Su JH, Liu CI. Flaccidoxide-13-acetate-induced apoptosis in human bladder cancer cells is through activation of p38/JNK, mitochondrial dysfunction, and endoplasmic reticulum stress regulated pathway. *Mar Drugs*. 2019;17:5. doi:10.3390/md17050287
12. Shin SS, Ko MC, Park YJ, et al. Hydrangenol inhibits the proliferation, migration, and invasion of EJ bladder cancer cells via p21WAF1-mediated G1-phase cell cycle arrest, p38 MAPK activation, and reduction in Sp-1-induced MMP-9 expression. *EXCLI J*. 2018;17:531–543.
13. Terauchi K, Kobayashi H, Yatabe K, et al. The NAD-dependent deacetylase sirtuin-1 regulates the expression of osteogenic transcriptional activator runt-related transcription factor 2 (runx2) and production of matrix metalloproteinase (MMP)-13 in chondrocytes in osteoarthritis. *Int J Mol Sci*. 2016;17:7. doi:10.3390/ijms17071019
14. Lin X, Chen Q, Xiao Y, et al. Phosphate glass fibers facilitate proliferation and osteogenesis through Runx2 transcription in murine osteoblastic cells. *J Biomed Mater Res A*. 2020;108(2):316–326. doi:10.1002/jbm.a.36818
15. Zhao X, Ji Z, Xie Y, Liu G, Li H. MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2. *Oncol Rep*. 2017;38(5):2727–2734. doi:10.3892/or.2017.5992
16. Ge C, Zhao G, Li Y, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. *Oncogene*. 2016;35(3):366–376. doi:10.1038/ncr.2015.91
17. Wen S, Zeng M, Li Y, et al. Downregulation of MANCR inhibits cancer cell proliferation in mantle cell lymphoma possibly by interacting with RUNX2. *Acta Biochim Biophys Sin*. 2019;51(11):1142–1147.
18. Abdelzaher E, Kotb AF. High coexpression of runt-related transcription factor 2 (RUNX2) and p53 independently predicts early tumor recurrence in bladder urothelial carcinoma patients. *Appl Immunohistochem Mol Morphol*. 2016;24(5):345–354. doi:10.1097/PAI.0000000000000193
19. Zhang FL, Cao JL, Xie HY, et al. Cancer-associated MORC2-mutant M276I regulates an hnRNP-mediated CD44 splicing switch to promote invasion and metastasis in triple-negative breast cancer. *Cancer Res*. 2018;78(20):5780–5792.
20. Zhang W, Guo H, Jing H, et al. Lactoferrin stimulates osteoblast differentiation through PKA and p38 pathways independent of lactoferrin's receptor LRP1. *J Bone Miner Res*. 2014;29(5):1232–1243.
21. Gills JJ, Castillo SS, Zhang C, et al. Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38 α , through MKK3/6-independent and -dependent mechanisms. *J Biol Chem*. 2007;282(37):27020–27029. doi:10.1074/jbc.M701108200
22. Igea A, Nebreda AR. The stress kinase p38 α as a target for cancer therapy. *Cancer Res*. 2015;75(19):3997–4002. doi:10.1158/0008-5472.CAN-15-0173
23. Campbell RM, Anderson BD, Brooks NA, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. *Mol Cancer Ther*. 2014;13(2):364–374. doi:10.1158/1535-7163.MCT-13-0513
24. Liu J, Yu X, Yu H, et al. Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B. *Cancer Med*. 2020;9(3):1183–1195. doi:10.1002/cam4.2795
25. Huang XH, Wang Y, Hong P, et al. Benzethonium chloride suppresses lung cancer tumorigenesis through inducing p38-mediated cyclin D1 degradation. *Am J Cancer Res*. 2019;9(11):2397–2412.
26. Yang JX, Xie P, Li YS, Wen T, Yang XC. Osteoclast-derived miR-23a-5p-containing exosomes inhibit osteogenic differentiation by regulating Runx2. *Cell Signal*. 2020;70:109504. doi:10.1016/j.cellsig.2019.109504
27. Wang ZQ, Keita M, Bachvarova M, et al. Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. *PLoS One*. 2013;8(10):e74384. doi:10.1371/journal.pone.0074384
28. Niu DF, Kondo T, Nakazawa T, et al. Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. *Lab Invest*. 2012;92(8):1181–1190. doi:10.1038/labinvest.2012.84
29. Huang W, Lu Y, Wang F, Huang X, Yu Z. Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression. *Gene*. 2018;678:337–342. doi:10.1016/j.gene.2018.08.036
30. Xin BC, Wu QS, Jin S, Luo AH, Sun DG, Wang F. Berberine promotes osteogenic differentiation of human dental pulp stem cells through activating EGFR-MAPK-runx2 pathways. *Pathol Oncol Res*. 2020;26(3):1677–1685. doi:10.1007/s12253-019-00746-6
31. Artigas N, Ureña C, Rodríguez-Carballo E, Rosa JL, Ventura F. Mitogen-activated protein kinase (MAPK)-regulated interactions between Osterix and Runx2 are critical for the transcriptional osteogenic program. *J Biol Chem*. 2014;289(39):27105–27117. doi:10.1074/jbc.M114.576793
32. Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. *Annu Rev Cell Dev Biol*. 2013;29:63–79. doi:10.1146/annurev-cellbio-101512-122347
33. Greenblatt MB, Shim JH, Zou W, et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. *J Clin Invest*. 2010;120(7):2457–2473. doi:10.1172/JCI42285
34. Chava S, Chennakesavulu S, Gayatri BM, Reddy A. A novel phosphorylation by AMP-activated kinase regulates RUNX2 from ubiquitination in osteogenesis over adipogenesis. *Cell Death Dis*. 2018;9(7):754. doi:10.1038/s41419-018-0791-7
35. Zhu W, He X, Hua Y, Li Q, Wang J, Gan X. The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation. *J Biol Chem*. 2017;292(27):11178–11188. doi:10.1074/jbc.M116.772277
36. Lu Q, Lu D, Shao ZM, Li DQ. Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells. *Cancer Sci*. 2019;110(4):1268–1278. doi:10.1111/cas.13953
37. Liu Q, Zhang S, Chen G, Zhou H. E3 ubiquitin ligase Nedd4 inhibits AP-1 activity and TNF- α production through targeting p38 α for polyubiquitination and subsequent degradation. *Sci Rep*. 2017;7(1):4521. doi:10.1038/s41598-017-04072-2

Cancer Management and Research**Dovepress****Publish your work in this journal**

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>